Our team has been exploring the peptide space for years
Hepatocytes: the powerhouse of biotransformation
A similar trend was observed in REWIND, where sustained benefits emerged with extended treatment exposure, suggesting that younger people, by virtue of prolonged therapy duration, may accrue a greater cumulative benefit from GLP-1 RAs [41], potentially explaining the more marked death reduction observed in this subgroup within our study
In laboratory and pre-clinical settings, the CJC-1295 Without DAC + Ipamorelin combination has been studied as a dual-pathway tool for investigating GH axis biology
Serum samples were diluted three times with normal saline before analysis
2026 Update: In the SURMOUNT-5 head-to-head trial, tirzepatide produced ~47% more weight loss than semaglutide over 72 weeks